Q
QuantAbundance

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

30,897 signal articles · 185 in last 24h · 157,635 total before filter · latest 4h ago
185last 24h
860last 7d
138● bullish (7d)
80● bearish (7d)
214publishers
AllMacro193Earnings142M&A102Regulatory18Product16Analyst24
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
3 Cash-Producing Stocks with Open Questions
StockStory7d agoneutral
3 Cash-Producing Stocks with Open Questions

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Why Novo Nordisk investors feel disappointed today
Yahoo Finance Video7d agoneutralVIDEO
Why Novo Nordisk investors feel disappointed today

Novo Nordisk (NVO) stock is dipping after the company's outlook disappointed investors. Yahoo Finance Executive Editor Brian Sozzi shares his thoughts on the stock, the company's trajectory, and where Eli Lilly (LLY) fits into the equation.

Why Micron and Dell stocks may have more juice than Nvidia
Yahoo Finance Video7d agoneutralVIDEO
Why Micron and Dell stocks may have more juice than Nvidia

Yahoo Finance Executive Editor Brian Sozzi goes 1-on-1 with EMJ Capital Founder and President Eric Jackson to discuss the next set of tech stocks after memory that can grow exponentially during the AI boom and why Jackson is willing to bet on Dell (DELL) and Micron (MU).

3 Inflated  Stocks We Think Twice About
StockStory7d agoneutral
3 Inflated Stocks We Think Twice About

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

What Would It Take For Pfizer To Cut Its Dividend?
Trefis7d agoneutral
What Would It Take For Pfizer To Cut Its Dividend?

Pfizer (PFE) has returned 23.1% over the past year and trades about 5% below its three-year high. Yet one question keeps coming back on its earnings calls: would it ever cut the dividend? An analyst asked it outright on the August call, and another tied it to a big acquisition in May. So what would a cut take, and what would it change.